Shanghai, December 27, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received the 2023 Prime Employers for Women Award for the second consecutive year at the ceremony held by sHero, a non-profit organization championing, leading and specializing in Diversity, Equity and Inclusion (DE&I) since 2011, placing it among the best employers for women that has made outstanding contribution to advancing DE&I in the workplace.
WuXi Biologics was also profiled in Driving DE&I China Best Practices Guide 2023 (“the Guide”) for its unwavering efforts in advocating DE&I through comprehensive initiatives across its global sites. The Guide features best-practice cases of 32 well-known global companies from various industries to help more organizations rise to a greater DE&I level in their workplace.
Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “We are quite glad to receive this recognition. At WuXi Biologics, we believe that a diverse and inclusive workforce is essential for fostering new ideas, perspectives, and developing solutions that can make positive impacts on our clients and patients worldwide. We are committed to providing an equal and inclusive environment for talents with different backgrounds, and enabling every employee to reach their full potential.”
In 2023, the company has made great progress to foster DE&I. March was an exciting month for WiSTEM campaign, with inspiring speeches, engaging roundtable discussions and offline networking taking place. In May, the company established a DE&I Committee as the highest-level management body to oversee and further advance DE&I efforts. Additionally, it encourages girls who have interest in STEM through science camps, as part of the global WiSTEM program, empowering young women to pursue science and technology careers, develop skills, and gain confidence.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.